Adjuvant chemotherapy using cisplatin by subcutaneous administration

In Vivo

Volumn 11, Issue 4, 1997, Pages 345-350

  Dernell, William S ^a   Withrow, Stephen J ^a   Straw, Rodney C ^b   Lafferty, Mary H ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b West Chermiside Veterinary Clinic   (Australia)

Author keywords

Adjuvant chemotherapy; Cisplatin; Dog; Subcutaneous administration

Indexed keywords

CARBOPLATIN; CISPLATIN;

ADJUVANT CHEMOTHERAPY; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; NEPHROTOXICITY; NONHUMAN; SARCOMA; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030869901     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. O'Brien MG, Withrow SJ, Straw RC: Recent advances in the treatment of canine appendicular osteosarcoma. Comp Cont Ed Pract Vet 15: 939-946, 1993.
2. Straw RC, Withrow SJ, Richter SL et al: Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Int Med 5: 205-210, 1991.
3. London CA, MacEwen EG, Kurzman ID, Vail DM: Distribution of metastasis in dogs with appendicular osteosarcoma receiving liposome encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE). Proc Vet Cancer Soc Monterey, CA: 46-47.(Abstract), 1993.
4. Kraegel SA, Madewell BR, Simonson E, Gregory CR: Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989). J Am Vet Med Assoc 199: 1057-1059, 1991.
5. Moore AS: Recent advances in chemotherapy for nonlymphoid malignant neoplasms. Comp Cont Ed Pract Vet 15: 1039-1045, 1993.
6. Withrow SJ, Straw RC: Local slow release cisplatin after limb sparing for canine osteosarcoma. Proc Eur Muskuloskel Oncol Soc, Florence, Italy 35(Abstract), 1995.
7. Withrow SJ, Straw RC, Brekke JH et al: Slow release adjuvant cisplatin for treatment of metastatic canine osteosarcoma. Eur J Muskuloskel Res 4: 105-110, 1995.
8. Kodama K, Doi O, Tatsuta M, Kuriyama K, Tateishi R: Development of postoperative intrathoracic chemo-thermotherapy for lung cancer with objective of improving local cure. Cancer 64: 1422-1428, 1989.
9. Speyer JL: Intraperitoneal cisplatin with IV therapy. Cancer Invest 7: 613-614, 1896.
10. Gibaldi M, Perrier D: Pharmacokinetics. New York: Marcel Dekker, 1982.
11. Zakris LE, Dewhirst MW, Riviere JE, Hoopes PJ, Page RL, Oleson JR: Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J Clin Oncol 5: 1613-1620, 1987.
12. ten Bokkel Huinink WW, Dubbelman R, Aartsen E, Franklin H, McVie JG: Experimental and clinical results with intraperitoneal cisplatin. Sem Oncol 12: 43-46, 1985.
13. Lewis KP, Medina WD: Cellulitis and fibrosis due to cis-diamminedichloroplatinum (II) (Platinol) infiltration. Cancer Treat Rep 64: 1162-1163, 1980.
14. Ogilvie GK, Straw RC, Jameson VJ et al: Prevalence of nephrotoxicosis associated with a four-hour saline solution diuresis protocol for the administration of cisplatin to dogs with naturally developing neoplasms. J Am Vet Med Assoc 202: 1845-1848, 1993.
15. Moore AS, Kirk C, Cardona A: Intracavitary cisplatin chemotherapy experience in six dogs. J Vet Int Med 5: 227-231, 1991.
16. Page RL: Cisplatin, a new antineoplastic drug in veterinary medicine. J Am Vet Med Assoc 186: 288-290, 1985.
17. Berg J, Weinstein MJ, Schelling SH, Rand WM: Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb sparing surgery: 22 cases (1987-1990). J Am Vet Med Assoc 200: 2005-2008, 1992.
18. Shapiro W, Fossum TW, Kitchell BE, Couto CG, Theilen GH: Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 192: 507-511, 1988.
19. Ogilvie GK, Straw RC, Powers BE: Prevalence of nephrotoxicosis associated with a short term diuresis protocol for the administration of cisplatin to dogs with malignant tumors: 61 cases (1987-1989). J Am Vet Med Assoc 199: 613-616, 1991.
20. Forrester SD, Fallin EA, Saunders GK, Kenny JE: Prevention of cisplatin-induced nephrotoxicosis in dogs using hypertonic saline as the vehicle of administration. Am J Vet Res 54: 2175-2178, 1993.
21. Ogilvie GK, Fettman MJ, Jameson VJ et al: Evaluation of a one-hour saline diuresis protocol for administration of cisplatin to dogs. Am J Vet Res 53: 1666-1669, 1992.
22. Baggot JD: Disposition and fate of drugs in the body. In: Booth NH, McDonald CE., eds. Veterinary Pharmacology and Therapeutics. Ames: Iowa State University Press 38-71, 1985:
23. Von Hoff DD, Schilsky R, Reichert CM: Toxic effects of cis-dichlorodiammineplatinum II in man. Cancer Treat Rep 63: 1527-1532, 1979.
24. Ogilvie GK, Moore AS, Curtis CR: Evaluation of cisplatin induced emesis in dogs with malignant neoplasia: 115 cases (1984-1987). J Am Vet Med Assoc 195: 1399-1403, 1989.
25. Algarra SM, Dy C, Bilbao I, Aparicio LA: Cutaneous necrosis after intra-arterial treatment with cisplatin. Cancer Treat Rep 70: 687-688, 1986.
26. Buchanan GR, Buchsbaum HJ, O'Banion K, Gojer B: Extravisation of dactinomycin, vincristine and cisplatin: Studies in an animal model. Med Pediatr Oncol 13: 375-380, 1985.
27. Snyderman ML, Wetmore SJ, Suen YJ: Cisplatin sensitization to radiotherapy in stage IV squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 112: 1147-1150, 1986.
28. Vermorken JB, van der Vijgh WJF, Klein I et al: Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 39: 136-144, 1986.
29. Desoize B, Marechal F, Millart H, Cattan A: Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity. Biomed Pharmacother 45: 203-207, 1991.